Figure_2.tif (598.2 kB)

Ceacam1 regulates GVHD target organ damage.

figure

posted on 2011-07-06, 02:40 authored by Sydney X. Lu, Lucy W. Kappel, Anne-Marie Charbonneau-Allard, Renée Atallah, Amanda M. Holland, Claire Turbide, Vanessa M. Hubbard, Jimmy A. Rotolo, Marsinay Smith, David Suh, Christopher King, Uttam K. Rao, Nury Yim, Johanne L. Bautista, Robert R. Jenq, Olaf Penack, Il-Kang Na, Chen Liu, George Murphy, Onder Alpdogan, Richard S. Blumberg, Fernando Macian, Kathryn V. Holmes, Nicole Beauchemin, Marcel R. M. van den Brink

A) 5×10⁶ TCD-BM ± 1×10⁶ T→BALB/c. Day 21. Histopathology score. N = 5–12/group. SB, small bowel. LB, large bowel. B) Thymocyte count and apoptotic skin cells from (A). N≥7/group. Day 21. One of two representative experiments. C) Apoptotic skin cells from (A). N≥7/group. Day 21. D) 5×10⁶ TCD-BM ± 1×10⁶ T→BALB/c. Histopathology score. Day 21. N≥7/group. SB, small bowel. LB, large bowel. E) Thymocyte counts from (E): N≥7/group. One of two independent experiments. DP: CD4⁺CD8⁺ double-positive thymocytes. Day 21. F) Apoptotic skin cells from (E). N≥7/group. Day 21. G) 5×10⁶ TCD-BM ± 1×10⁶ T→WT or Ceacam1^−/− BALB/c. Histopathology score. Day 14. N≥12/group. SB, small bowel. LB, large bowel. H) Thymocyte count from (I). N≥8/group. One of two independent experiments. DP: CD4⁺CD8⁺ double-positive thymocytes. Day 14.